

Reduced Efficacy of a Src Kinase Inhibitor in Crowded Protein Solution

Kento Kasahara

RIKEN Center for Biosystems Dynamics Research

Suyong Re

RIKEN Center for Biosystems Dynamics Research

Grzegorz Nawrocki

Michigan State University

Hiraku Oshima

Chiemi Mishima-Tsumagari

RIKEN Centre for Life Science Technologies

Mutsuko Kukimoto-Niino

RIKEN Systems and Structural Biology Centre

Isseki Yu

Maebashi Institute of Technology

Mikako Shirouzu

RIKEN Center for Biosystems Dynamics Research <https://orcid.org/0000-0002-7997-2149>

Michael Feig

Michigan State University

Yuji Sugita (✉ sugita@riken.jp)

RIKEN <https://orcid.org/0000-0001-9738-9216>

Article

Keywords: Inhibitor Binding, Atomistic Molecular Dynamics, Crowded Cellular Environment

Posted Date: September 17th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-72438/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Nature Communications on July 2nd, 2021.
See the published version at <https://doi.org/10.1038/s41467-021-24349-5>.

1 **Reduced Efficacy of a Src Kinase Inhibitor in Crowded Protein**
2 **Solution**

3 **Author Information**

4
5 Kento Kasahara^a, Suyong Re^a, Grzegorz Nawrocki^b, Hiraku Oshima^a, Chiemi Mishima-Tsumagari^c,
6 Mutsuko Kukimoto-Niino^c, Isseki Yu^d, Mikako Shirouzu^c, Michael Feig^b, and Yuji Sugita^{a,e,f}

7
8 ^aLaboratory for Biomolecular Function Simulation, RIKEN Center for Biosystems Dynamics Research,
9 6-7-1 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.

10 ^bDepartment of Biochemistry and Molecular Biology, Michigan State University, 630 Wilson Road, 218
11 Biochemistry Building, East Lansing, Michigan 48824-1319, United States.

12 ^cLaboratory for Protein Functional and Structural Biology, RIKEN Center for Biosystems Dynamics
13 Research, 1-7-22 Suehiro-cho, Tsurumi, Yokohama, Kanagawa 230-0045, Japan.

14 ^dDepartment of Life Science and Informatics, Maebashi Institute of Technology, Kamisadori-machi,
15 Maebashi, Gunma 371-0816, Japan.

16 ^eComputational Biophysics Research Team, RIKEN Center for Computational Science, 6-7-1
17 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.

18 ^fTheoretical Molecular Science Laboratory, RIKEN Cluster for Pioneering Research, Hirosawa 2-1,
19 Wako, Saitama 351-0198, Japan.

20 **Contributions**

21 K.K., G.N., and H.O. performed simulations. K.K. analyzed data. K.K., S.R., and I.Y. modelled
22 simulation systems. C.M.T., M.K.N., and M.S. carried out experiments. K.K., S.R., M.F., and Y.S. wrote
23 manuscript. M.F. and Y.S. designed and initiated the research.

24 **Corresponding author**

25 Correspondence to: Michael Feig (mfeiglab@gmail.com), Yuji Sugita (sugita@riken.jp)

26 ORCID

27 Kento Kasahara (<https://orcid.org/0000-0001-7138-250X>)

28 Suyong Re (<https://orcid.org/0000-0002-3752-6554>)

29 Hiraku Oshima (<https://orcid.org/0000-0001-5626-1291>)

30 Mutsuko Kukimoto-Niino (<https://orcid.org/0000-0002-4178-1611>)

31 Michael Feig (<https://orcid.org/0000-0001-9380-6422>)

32 Yuji Sugita (<https://orcid.org/0000-0001-9738-9216>)

33

34 **Abstract**

35 The inside of a cell is highly crowded with proteins and other biomolecules. How proteins express their
36 specific functions together with many off-target proteins in crowded cellular environments is largely
37 unknown. Here, we investigate an inhibitor binding with c-Src kinase using atomistic molecular dynamics
38 (MD) simulations in dilute as well as crowded protein solution. The populations of the inhibitor, PP1, in
39 bulk solution and on the surface of c-Src kinase are reduced as the concentration of crowder bovine serum
40 albumins (BSAs) increases. This observation is consistent with the reduced PP1 inhibitor efficacy in
41 experimental c-Src kinase assays in addition with BSAs. The crowded environment changes the major
42 binding pathway of PP1 toward c-Src kinase compared to that in dilute solution. This change is explained
43 based on the population shift mechanism of local conformations near the inhibitor binding site in c-Src
44 kinase. Protein functions in a living cell could be examined using atomistic MD simulations with realistic
45 cellular environments.

46 **Introduction**

47 Understanding of protein functions in a living cell is one of the essential issues in molecular biology and
48 biochemistry. *In vitro* experiments on protein or enzyme functions often reveal different results from *in*
49 *vivo* experiments. In a typical cytoplasm, 25-45% of the total volume is occupied by macromolecules
50 including many proteins, nucleic acids, metabolites, osmolytes, and ions^{1,2}. The crowded environment
51 affects protein structure, stability, dynamics, and biological functions slightly or significantly^{3,4}. Recent
52 experimental⁵⁻⁹ and theoretical studies¹⁰⁻¹⁶ have shown that weak and non-specific molecular interactions
53 are equally important with the excluded volume effect that has been emphasized in the traditional theory
54 on macromolecular crowding^{2,4}. For instance, in-cell NMR spectroscopy has shown reduced
55 conformational stability of ubiquitin in HeLa cells compared to those in dilute solution. The traditional
56 theory, however, suggested that compact native structures of proteins are preferred in crowded cellular
57 environments⁷.

58 Substrate (or ligand) binding to a target protein is an essential process that controls a variety of biological
59 functions including enzymatic reactions, substrate transports, signal transductions, and so on. The well-
60 established concepts like “lock-and-key”, “induced-fit”, or “conformational selection” have been used to
61 interpret the binding processes¹⁷ as well as to design new drug candidates^{18,19}. Protein conformational
62 flexibility has been regarded as more important in substrate bindings so that atomistic molecular dynamics
63 (MD) simulations are often conducted in *in-silico* drug discovery²⁰. In spite of these efforts, many designed
64 drug candidates lack *in vivo* efficacy and cannot be applied to the patients who are suffering from diseases.
65 One of the missing factors in current drug discovery protocols might be the effect of cellular environments
66 on protein-ligand bindings and functions. There is increasing experimental evidence that supports the
67 importance of cellular environments for the thermodynamics and kinetics of protein-ligand binding^{3,21}. For
68 instance, the efficacy of inhibitors of threonine tyrosine kinases in cells is reduced significantly in many
69 cases compared to that in dilute solution²².

70 Recently, the accessible time scale of MD simulation has been greatly extended due to the developments
71 of MD-special purpose supercomputers, Anton/Anton2^{23,24} and enhanced conformational sampling
72 algorithms including replica exchange methods^{25,26}, metadynamics^{27,28}, Gaussian accelerated MD

73 (GaMD)²⁹, and scaled MD^{30,31}. Parallel MD simulations based on weighted-ensemble method³²⁻³⁴, parallel
74 cascade selection MD (PaCS-MD)³⁵, Markov state model (MSM)³⁶ are also useful to predict
75 thermodynamic and kinetic properties of biomolecules. Using these advanced techniques, absolute binding
76 free energies and/or kinetic parameters, namely, k_{on} or k_{off} , in dilute solution have been successfully
77 predicted. Atomic MD simulations of multiple proteins in crowded environments revealed different aspects
78 of proteins, such as translational or rotational diffusion^{13,37}, solvation structure and dynamics^{12,14}, and the
79 conformational stability of proteins^{10,12}. The importance of metabolites including adenosine triphosphate
80 (ATP) on protein structures and interactions was suggested in large-scale MD simulations of the cytoplasm
81 in *Mycoplasma genitalium*¹⁵. Independent experiments also suggested that ATP works as a hydrotrope in
82 cells³⁸.

83 Here, we study protein functions in crowded protein solutions by performing multiple μ sec MD simulations
84 using Anton2 and other supercomputers (~ 100 μ sec, in total). In the study, we focus on a small inhibitor
85 (PP1) binding to c-Src kinase in dilute solution and crowded environments with bovine serum albumins
86 (BSAs) as protein crowders. BSA has been shown to not change the conformational stability of the other
87 protein in crowded solution⁶. c-Src kinase (Supplementary Fig. 1) regulates various signal transduction
88 pathways by catalyzing phosphate transfer from ATP to a target substrate³⁹. Dysregulation of this kinase
89 function is associated with many diseases like cancer, making it an important therapeutic target. To design
90 drug candidates, both the active and inactive conformations of c-Src kinase⁴⁰⁻⁴⁵ as well as the ligand binding
91 process^{43,46-48} have been extensively investigated in dilute solution. PP1 was designed to inhibit the kinase
92 function by binding to the ATP binding site (the canonical binding site) of c-Src kinase (Supplementary
93 Fig. 2)⁴⁹. A recent computational study using the two-dimensional replica-exchange method characterizes
94 the multiple binding poses and binding pathways of PP1 to c-Src kinase from the encounter state^{48,50}. We
95 performed atomistic MD simulations of four c-Src kinase/PP1/BSA systems, each of which contains 0
96 (dilute solution), 2, 4, and 8 BSAs in a simulation box with the same size (referred to as Src2BSA, Src4BSA,
97 and Src8BSA, respectively). The observations in the simulations provide a microscopic picture of protein-


98 inhibitor binding in crowded solution, deepening our understanding of protein function in a living cell and
99 proposing a new strategy for *in-silico* drug discovery.

100 **Results**

101 Structural stability and flexibility of c-Src kinase

102 We first examine the effect of crowded environments on the structural stability and flexibility of c-Src
103 kinase. The C α root mean square deviations (RMSDs) from the X-ray structure are observed around 2-3 Å
104 in all the simulations, indicating that the kinase remains in the active conformation (Supplementary Fig. 3).
105 The time averages of the RMSD values in the presence of BSA (~2.4 Å) are slightly smaller than that in
106 the absence of BSA (~2.6 Å) (Supplementary Fig. 4(a)). ϵ in the inhibitor-unbound state are also not
107 affected by the presence of the BSAs (Supplementary Fig. 4(b)), where the unbound state is defined when
108 the protein-PP1 distance, ξ , is longer than 15 Å (Supplementary Fig. 5).

109 PP1 distributions in water and on the protein surfaces



110

111 **Fig. 1:** Spatial distribution functions (SDF) of (a) PP1 and (b) BSA around c-Src kinase. In the case of
112 BSA-SDF, C α atoms are used for analysis. The PP1-SDF is shown as isosurface at 0.5% (transparent) and
113 1.5% occupancies (solid). For BSA-SDF, the isosurface at 1.0% occupancy is shown.


114

115 The interaction between c-Src kinase and PP1 was examined based on the spatial distribution function (SDF)
116 of PP1 around the kinase. The SDF in the absence of BSA illustrates the existence of many non-canonical
117 binding sites beside the canonical ATP-binding one, which is consistent with previous findings in long MD
118 simulations using Anton⁵¹ (Fig. 1(a) and Supplementary Fig. 6). The PP1 non-canonical binding sites
119 eventually disappear as the BSA concentrations increase. The surface region of c-Src kinase in the crowded
120 solutions is largely occupied by BSAs (Fig. 1(b) and Supplementary Fig. 7). Since the canonical binding
121 site exists at the cleft formed between the N- and C-lobes, BSA cannot cover it. A lot of PP1 stays on the
122 surface of BSA in the crowded solutions, due to weak and non-specific interactions between PP1 and BSAs
123 (Supplementary Fig. 8). The reduced PP1 distribution around c-Src kinase in the crowded solutions is, thus,
124 explained via both the steric hinderance of BSAs (Supplementary Fig. 7) and the weak and non-specific
125 interactions between PP1 and BSAs (Supplementary Fig. 8).

126 We also investigated the population of PP1 in the bulk water region, which is at least 5 Å away from any
127 heavy atom of c-Src kinase or BSAs (Supplementary Fig. 9). The space within 5 Å of any heavy atom of
128 c-Src kinase (or BSA) is defined as the surface region of c-Src kinase (or BSA). In dilute solution, 79.9%
129 of PP1 exist in the water phase, while the probability dropped to 1.8% in Src8BSA (Fig. 2 (a)). The PP1
130 population on the surface of c-Src kinase also decreased from 20.1% (dilute) to 8.3% (Src8BSA) as the
131 protein volume fraction increased. Contrarily, the population on the BSA surfaces increased from 55.3%
132 (Src2BSA) to 89.9% (Src8BSA). If we divide the probability by the number of BSAs in a simulation box,
133 the values for Src2BSA, Src4BSA, and Src8BSA become 27.7, 20.0, and 11.2%, respectively, which are

134 still larger than those on the c-Src kinase surface at the same protein concentration (Supplementary Tables
135 4 and 5, Supplementary Fig. 10).

136 *In vitro* inhibitory assays in the presence or absence of BSA



137
138 **Fig. 2:** Reduced efficacy of PP1 inhibitor in the presence of the crowder (BSA) proteins. (a) The probability
139 of finding PP1 in the bulk water region, on c-Src kinase, and on the BSAs as functions of the protein volume
140 fraction. (b) Enzymatic activity of c-Src kinase in the dilute solution ($[c\text{-Src}] = 65.7 \text{ nM}$) and in the


141 crowded solution ($[c\text{-Src}] = 65.7 \text{ nM}$, $[\text{BSA}] = 12.7 \mu\text{M}$ (5 mg/ml)). Error bars of (a) and (b) represent
142 the standard error of the mean from seven trajectories and three independent assays, respectively.

143
144 Based on the PP1 populations in the bulk water region and on the protein surfaces, we predict that the
145 inhibitor efficacy is reduced in crowded environments compared to that in dilute solution. *In vitro* PP1
146 inhibition assays with c-Src kinase, Src substrate, and ATP, were performed in the presence or absence of
147 BSA to test this hypothesis. To avoid aggregation in the protein solution, the protein concentration in the
148 experiments was much lower than in the simulations. The c-Src kinase concentration was set to 65.7 nM in
149 the absence of BSA, while the BSA concentration was much larger ($12.7 \mu\text{M} = 5 \text{ mg/ml}$) than kinase (65.7
150 nM) to realize a crowded protein solution. The 50% inhibition concentration (IC_{50}) of the PP1 considerably
151 increased from 33.80 nM to 290.4 nM in the presence of BSA (Fig. 2(b)). This validates our hypothesis of
152 a reduced inhibitor efficacy in crowded protein solutions.

153 Slow-down of PP1 diffusion in crowded solution

154 The mean square displacements (MSDs) of PP1 were analyzed in the bulk water region, on the surfaces of
155 c-Src kinase or BSA. PP1 diffusion in the bulk water region slowed down as the protein volume fraction
156 increased (Supplementary Fig. 11(a)). PP1 diffusion on the protein surfaces is nearly identical to diffusion
157 of c-Src kinase or BSA in Src4BSA and Src8BSA (Supplementary Figs. 11(b) and (c)). In the crowded
158 solutions, the probability of finding PP1 on the protein surfaces is much higher than that in the bulk water
159 region (Fig. 2(a)). PP1 diffusion is thus significantly affected by proteins in the crowded solutions as PP1
160 mostly diffuses along with the proteins while bound to it. This is further manifested by long residence times
161 on the 1-100 ns time scale for PP1 association with the c-Src kinase and BSA as shown in Supplementary
162 Table 6.

163 Ligand-binding pathways in crowded environments



164

165 **Fig. 3:** Binding trajectories projected onto the two-dimensional free energy landscapes (FELs) obtained
 166 from the gREST/REUS simulations in the dilute solution. (a) Definition of azimuth angles (θ , ϕ) for
 167 describing the relative position (See Supporting information for the detail). (b) The major binding
 168 pathway in the dilute solution obtained from the gREST/REUS simulation in different conditions. Left
 169 panel: simulation without any restraints (free), Right panel: simulation in which the residues outside the
 170 binding pocket is kept close to the crystal structure. **E**, **I**, **B***, and **B** respectively indicate encounter
 171 complex, intermediate, pre-bound, and bound states. The subscript r denotes the presence of the restraints.
 172 (c, d) The binding trajectories in the dilute solution and in the crowded solution (Src8BSA) projected onto
 173 the 2D-FEL from ‘free’ simulation and that from ‘restraint’ simulation, respectively.

174


175 In the present simulations, we observed four and two PP1 binding events to the canonical binding site in
 176 the dilute solution and Src8BSA, respectively (Supplementary Figs. 12 and 13). In dilute solution, PP1
 177 approaches to the canonical binding site from the glycine rich loop (G-loop) in c-Src kinase. This binding
 178 pathway is different from that observed in Src8BSA: PP1 first reaches the hinge region of the kinase and

179 then intrudes into the canonical binding site. These binding trajectories are projected onto the two free
180 energy landscapes (FELs) that were obtained in our previous study on the same system in dilute solution
181 using the gREST/REUS simulations⁴⁸ (Fig. 3 and Supplementary Figs. 14-16). The two-dimensional FELs
182 illustrate the changes in free energy along the c-Src kinase-PP1 distance (ξ) and one of the coordinates (an
183 azimuth angle θ) representing the PP1 position with respect to c-Src kinase (Fig. 3(a)). Two FELs were
184 computed in two different conditions: in one simulation, c-Src kinase fluctuated freely (referred to as ‘free’)
185 (Fig. 3(b) and Supplementary Fig. 14(a)), while strong positional restraints to the kinase prohibited the
186 kinase flexibilities in the other simulation (referred to as ‘restraint’) (Fig. 3(b) and Supplementary Fig.
187 14(b)). On the major binding pathway in the ‘free’ FEL, PP1 approaches c-Src kinase from the small $\theta \sim$
188 60° (Supplementary Fig. 14(a)), while the binding pathway of the ‘restraint’ FEL starts from the large $\theta \sim$
189 120° (Supplementary Fig. 14(b)).

190 In the present simulations, we observed four and two PP1 binding events to the canonical binding site in
191 the dilute solution and Src8BSA, respectively (Supplementary Figs. 12 and 13). In dilute solution, PP1
192 approaches to the canonical binding site from the glycine rich loop (G-loop) in c-Src kinase. This binding
193 pathway is different from that observed in Src8BSA: PP1 first reaches the hinge region of the kinase and
194 then intrudes into the canonical binding site. These binding trajectories are projected onto the two free
195 energy landscapes (FELs) that were obtained in our previous study on the same system in dilute solution
196 using the gREST/REUS simulations⁴⁸ (Fig. 3 and Supplementary Figs. 14-16). The two-dimensional FELs
197 illustrate the changes in free energy along the c-Src kinase-PP1 distance (ξ) and one of the coordinates (an
198 azimuth angle θ) representing the PP1 position with respect to c-Src kinase (Fig. 3(a)). Two FELs were
199 computed in two different conditions: in one simulation, c-Src kinase fluctuated freely (referred to as ‘free’)
200 (Fig. 3(b) and Supplementary Fig. 14(a)), while strong positional restraints to the kinase prohibited the
201 kinase flexibilities in the other simulation (referred to as ‘restraint’) (Fig. 3(b) and Supplementary Fig.
202 14(b)). On the major binding pathway in the ‘free’ FEL, PP1 approaches c-Src kinase from the small $\theta \sim$

203 60° (Supplementary Fig. 14(a)), while the binding pathway of the 'restraint' FEL starts from the large $\theta \sim$
 204 120° (Supplementary Fig. 14(b)).

205 Conformational shifts of a Tyr sidechain upon crowding



206
 207 **Fig. 4:** Distribution of the TYR-in and TYR-out states of c-Src kinase. (a) Tyr-in state structure together
 208 with a binding trajectory in the dilute solution. (b) Tyr-out state structure with binding trajectory in the
 209 dilute and crowded solution (Src8BSA). Red, blue, and green spheres represent the PP1 bound position in
 210 the crystal structure, representative binding pathways in dilute and crowded solutions, respectively.
 211 Encounter states in the pathways are circled. (c) Distribution for Tyr82-Gly86 distance, $g(d)$. The distance
 212 between Tyr82 and Gly86 in a crystal structure of c-Src kinase in complex with an inhibitor (ID: 1Y57) is
 213 shown with dashed line for comparison⁵².

214

215 To examine the molecular mechanisms for why the binding pathways differ between dilute and crowded
216 solutions, we investigated local conformational changes in c-Src kinase as protein volume fraction
217 increased. We found two characteristic sidechain conformations of Tyr82 at the hinge region, which we
218 refer to as TYR-in and TYR-out. In TYR-in, two hydrophobic residues Leu15 and Gly86 sandwich Tyr82,
219 thereby blocking the pathway from the hinge region (Fig. 4(a)). PP1 thus interacts with G-loop to form the
220 encounter complex **E**. In TYR-out, on the other hand, G-loop shifts downward (~ 1 Å, Supplementary Fig.
221 17). Consequently, Tyr82 is positioned away from Leu15 and Gly86 (Fig. 4(b)), allowing PP1 access to the
222 hinge region at the encounter complex **E_r**. The distribution of Tyr82-Gly86 distance, $g(d)$, is centered
223 around $d = 5$ Å in TYR-in and $d = 8.5$ Å in TYR-out (Fig. 4(c)). TYR-in is dominant in the dilute condition,
224 while we observe TYR-out as a minor population. As the protein concentration increases (in the order of
225 Src2BSA, Src4BSA, and Src8BSA), the ratio between TYR-in and TYR-out is gradually changed. Finally,
226 TYR-out becomes the major population in Src8BSA.

227 In a crystal structure of c-Src kinase in complex with an inhibitor (PDB ID: 1Y57), the Tyr82-Gly86
228 distance is close to, but slightly different from that in TYR-out (Fig. 4(c)). Interestingly, a water molecule
229 exists between Tyr82 and Gly86 in the crystal structure of c-Src kinase in the apo form (PDB ID: 1YOJ)
230 (Supplementary Fig. 18). In the same position, we observe water densities in the MD snapshots where the
231 Tyr82 sidechain assumes the TYR-out structure (Supplementary Fig. 18).

232 **Discussion**

233 The crowding effects on c-Src kinase/PP1 binding can be categorized into two different types: 1) The
234 slowdown of PP1 diffusion, the decrease of non-canonical PP1 binding sites in the kinase, and the reduced
235 efficacy of the inhibitor are due to generic crowding effects. We expect similar effects with other proteins
236 under crowded conditions. 2) The different PP1 binding pathways in crowded vs. solution are specific to c-
237 Src kinase. Whether such an effect is present for other ligands and other enzymes is highly dependent on

238 the molecular details of a given system. Hereafter, we reconsider these two crowding effects based on the
239 traditional excluded volume effects as well as weak and non-specific molecular interactions in crowded and
240 cellular environments.

241 The slowdown of PP1 diffusion in crowded solutions is consistent with the traditional understanding of
242 crowding, which predicts that the kinetics of protein-ligand binding becomes slower under crowded
243 conditions due to increased solution viscosity³. Indeed, we found that the translational diffusion of PP1 and
244 water even in the bulk water region of the crowded solutions become slower (Supplementary Fig. 19). On
245 the protein surfaces, ligand diffusion was much more retarded due to non-specific interactions with proteins.
246 In our previous MD simulations of the *MG* cytoplasm, charged and/or large metabolites were also found to
247 stay on the protein surfaces for a long time, while hydrophobic metabolites like Val were found to remain
248 solvated in larger fractions¹⁵. The importance of non-specific interactions between macromolecular
249 crowders and substrates were also seen in a recent enzyme assay⁵³. Therefore, it is becoming evident that
250 the heterogeneous environments for proteins and ligands in crowded cellular conditions must be taken into
251 account to correctly estimate protein-ligand binding kinetics in a living cell. On the computational side, this
252 insight could be incorporated into Brownian dynamics (BD) based approaches⁵⁴⁻⁵⁷, which are commonly
253 used to predict protein-ligand binding kinetics for dilute conditions. The traditional theory of
254 macromolecular crowding predicts that protein-ligand and protein-protein interactions in crowded
255 environments would be stronger than those in dilute solution. The volume exclusion effect has been
256 considered as a main driving force^{21,58}. This effect suggests an increase of the effective concentration of the
257 substrates around the target macromolecule. For example, the activity of a DNA ligase correlates with an
258 increase in the effective concentration of the substrate due to crowding⁵⁹. Contrary, the present study shows
259 that the effective ligand concentration is reduced as a function of protein volume fraction, because target
260 protein-crowder interactions sterically block non-canonical binding sites. Ligands might be trapped on the
261 surfaces of crowder proteins. This is again consistent with the observations in our previous simulations of
262 the *MG* cytoplasm.¹⁵ Based on these common observations, we hypothesize that an effectively reduced

263 ligand concentration in soluble regions is common in crowded solution as well as cellular environments
264 like the cytoplasm. A decrease in the ligand concentration is expected to reduce the inhibitor efficacy in
265 these environments, as our kinase assay showed. In future work, binding free energy calculations under
266 crowded conditions could quantitatively address the relation between the effective inhibitor concentration
267 and its efficacy.

268 In Src8BSA simulations, the PP1 binding pathway is entirely different from that in dilute simulations. This
269 suggests that crowding effects could change protein-ligand binding mechanisms. The crystal structure of c-
270 Src kinase has a local structure similar to what is dominant in Src8BSA. However, the crystal environments
271 and crowded solutions are different conditions in terms of their flexibilities and molecular interactions with
272 nearby molecules. We observed an increasing shift in population of the local conformation of c-Src kinase
273 as crowding was increased. As shown in Supplementary Fig. 20, the transitions between Tyr-in and Tyr-
274 out forms occur dynamically. Even in the dilute solution, Tyr-out exists as a minor conformation. Due to
275 non-specific molecular interactions between crowder BSAs and the G-loop of c-Src kinase, Tyr-out
276 conformations are preferred in the crowded environment (see Supplementary Fig. 17). Therefore, in
277 addition to the macromolecular crowding effects on open-to-close conformations or folding/unfolding
278 equilibrium^{60,61}, small and local conformational shifts near the active site of proteins due to crowding may
279 change molecular mechanisms underlying their biological functions as we describe in this study.

280 We showed that the sidechain position of Tyr82 driven by the downward shift of the G-loop is the key
281 determinant for changing the PP1 binding pathway. It has been suggested previously that the downward
282 shift of the G-loop could impact drug efficacy²². Also, the sequence alignment data set of 490 kinases⁶²
283 (Supplementary Fig. 21) shows that about 44% of kinases share the tyrosine near the hinge region. In
284 addition, about 16% of the kinases have phenylalanine instead of tyrosine at the same position. Therefore,
285 the suggested role of Tyr82 as a key amino acid in the binding of ligands and inhibitors - and the possibility
286 to be sensitive to crowding effects suggested here - may be shared by a broad range of kinases.

287 **Methods**

288 **MD simulations**

289 The initial structure of c-Src kinase was prepared from an X-ray structure of unphosphorylated active-like
290 c-Src kinase (PDB: 1Y57)⁵². Similar to the previous conventional MD⁵¹ and the gREST/REUS
291 simulations⁴⁸, only the kinase domain (residues 82-258) was used in this study. A c-Src kinase and 24 mM
292 PP1 inhibitors were placed and then solvated by 150 mM NaCl aqueous solution (dilute). To represent
293 crowded protein solutions, bovine serum albumin (BSA) proteins (PDB: 4F5S)⁶³ are also included as
294 crowders. In Src2BSA, Src4BSA, and Src8BSA, two, four, and eight BSAs were simulated with c-Src
295 kinase and PP1. We used the AMBER ff99SB-ILDN^{64,65} and TIP3P⁶⁶ parameters for the proteins and water
296 molecules, respectively. The PP1 parameters were prepared with GAFF with AM1-BCC⁶⁷. For each system,
297 a set of different initial configurations was prepared. The simulations were performed with the GENESIS
298 software^{68,69} and with Anton2²⁴ in Pittsburg supercomputing center (PSC). Further detail is available as a
299 part of Supplementary Information.

300 **Protein expressions and purification**

301 The gene encoding human Src kinase domain (residues 260-533) was cloned into the pCR2.1 vector
302 (Invitrogen) and expressed as a fusion with N-terminal histidine and GST tags using *Escherichia coli* cell-
303 free reaction supplemented with chaperones and YopH^{70,71}. The protein was purified by affinity
304 chromatography using a HisTrap column (GE Healthcare) and further by ion exchange on a HiTrap Q
305 column (GE Healthcare) and used for *in vitro* kinase assay.

306 **In vitro inhibition assay**

307 *In vitro* inhibition assay was performed using the ADP-Glo Kinase Assay (Promega) under the conditions
308 based on the manufacturer's protocol. Briefly, purified Src protein (20 ng) was incubated with the indicated
309 concentrations of PP1 (Cayman Chemical), 100 µg/ml Src substrate (SignalChem Pharmaceuticals), and 10
310 µM ATP for 60 min at room temperature in a reaction solution containing 0.2% DMSO, 40 mM Tris-HCl

311 (pH7.5), 20 mM MgCl₂, 2 mM MnCl₂, 50 μM DTT with and without 5.0 mg/ml BSA. The reaction was
312 terminated by adding the ADP-Glo Reagent, and then ADP generation was detected using the luciferase
313 reaction by monitoring the luminescence on an ARVO X3 microscale luminometer (PerkinElmer). IC₅₀
314 was determined by curve fitting the data using the GraphPad Prism8 program (GraphPad software).

315 **Data Availability**

316 The trajectories are available from the corresponding authors upon reasonable request.

317 **Code Availability**

318 The source code of GENESIS (<https://www.r-ccs.riken.jp/labs/cbrt/>) is distributed under the GNU Lesser
319 General Public License version 3.

320 **References**

- 321 1. Minton, A. P. The influence of macromolecular crowding and macromolecular confinement on
322 biochemical reactions in physiological media. *J. Biol. Chem.* **276**, 10577–10580 (2001).
- 323 2. Rivas, G. & Minton, A. P. Macromolecular crowding in vitro, in vivo, and in between. *Trends*
324 *Biochem. Sci.* **41**, 970–981 (2016).
- 325 3. Kuznetsova, I., Zaslavsky, B., Breydo, L., Turoverov, K. & Uversky, V. Beyond the excluded
326 volume effects: mechanistic complexity of the crowded milieu. *Molecules* **20**, 1377–1409 (2015).
- 327 4. Zimmerman, S. B. & Minton, A. P. Macromolecular crowding: biochemical, biophysical, and
328 physiological consequences. *Annu. Rev. Biophys. Biomol. Struct.* **22**, 27–65 (1993).
- 329 5. Wang, Y., Li, C. & Pielak, G. J. Effects of proteins on protein diffusion. *J. Am. Chem. Soc.* **132**,
330 9392–9397 (2010).
- 331 6. Miklos, A. C., Sarkar, M., Wang, Y. & Pielak, G. J. Protein crowding tunes protein stability. *J.*
332 *Am. Chem. Soc.* **133**, 7116–7120 (2011).

- 333 7. Inomata, K. *et al.* High-resolution multi-dimensional NMR spectroscopy of proteins in human
334 cells. *Nature* **458**, 106–109 (2009).
- 335 8. Smith, A. E., Zhou, L. Z. & Pielak, G. J. Hydrogen exchange of disordered proteins in *Escherichia*
336 *coli*. *Protein Sci.* **24**, 706–713 (2015).
- 337 9. Ikeya, T., Güntert, P. & Ito, Y. Protein Structure Determination in Living Cells. *Int. J. Mol. Sci.*
338 **20**, 2442 (2019).
- 339 10. Feig, M. & Sugita, Y. Variable interactions between protein crowders and biomolecular solutes are
340 important in understanding cellular crowding. *J. Phys. Chem. B* **116**, 599–605 (2011).
- 341 11. Harada, R., Sugita, Y. & Feig, M. Protein crowding affects hydration structure and dynamics. *J.*
342 *Am. Chem. Soc.* **134**, 4842–4849 (2012).
- 343 12. Harada, R., Tochio, N., Kigawa, T., Sugita, Y. & Feig, M. Reduced native state stability in
344 crowded cellular environment due to protein–protein interactions. *J. Am. Chem. Soc.* **135**, 3696–
345 3701 (2013).
- 346 13. Nawrocki, G., Wang, P., Yu, I., Sugita, Y. & Feig, M. Slow-Down in Diffusion in Crowded
347 Protein Solutions Correlates with Transient Cluster Formation. *J. Phys. Chem. B* (2017).
- 348 14. Wang, P., Yu, I., Feig, M. & Sugita, Y. Influence of protein crowder size on hydration structure
349 and dynamics in macromolecular crowding. *Chem. Phys. Lett.* **671**, 63–70 (2017).
- 350 15. Yu, I. *et al.* Biomolecular interactions modulate macromolecular structure and dynamics in
351 atomistic model of a bacterial cytoplasm. *Elife* **5**, (2016).
- 352 16. von Bülow, S., Siggel, M., Linke, M. & Hummer, G. Dynamic cluster formation determines
353 viscosity and diffusion in dense protein solutions. *Proc. Natl. Acad. Sci.* **116**, 9843–9852 (2019).

- 354 17. Boehr, D. D., Nussinov, R. & Wright, P. E. The role of dynamic conformational ensembles in
355 biomolecular recognition. *Nat. Chem. Biol.* **5**, 789 (2009).
- 356 18. Friesner, R. A. *et al.* Glide: a new approach for rapid, accurate docking and scoring. 1. Method
357 and assessment of docking accuracy. *J. Med. Chem.* **47**, 1739–1749 (2004).
- 358 19. Forli, S. *et al.* Computational protein–ligand docking and virtual drug screening with the
359 AutoDock suite. *Nat. Protoc.* **11**, 905–919 (2016).
- 360 20. De Vivo, M., Masetti, M., Bottegoni, G. & Cavalli, A. Role of Molecular Dynamics and Related
361 Methods in Drug Discovery. *J. Med. Chem.* **59**, 4035–4061 (2016).
- 362 21. Kuznetsova, I., Turoverov, K. & Uversky, V. What macromolecular crowding can do to a protein.
363 *Int. J. Mol. Sci.* **15**, 23090–23140 (2014).
- 364 22. Uitdehaag, J. C. M. *et al.* Target residence time-guided optimization on TTK kinase results in
365 inhibitors with potent anti-proliferative activity. *J. Mol. Biol.* **429**, 2211–2230 (2017).
- 366 23. Shaw, D. E. *et al.* Anton, a special-purpose machine for molecular dynamics simulation. *Commun.*
367 *ACM* **51**, 91–97 (2008).
- 368 24. Shaw, D. E. *et al.* Anton 2: raising the bar for performance and programmability in a special-
369 purpose molecular dynamics supercomputer. in *Proceedings of the international conference for*
370 *high performance computing, networking, storage and analysis* 41–53 (2014).
- 371 25. Sugita, Y. & Okamoto, Y. Replica-exchange molecular dynamics method for protein folding.
372 *Chem. Phys. Lett.* **314**, 141–151 (1999).
- 373 26. Kokubo, H., Tanaka, T. & Okamoto, Y. Two-dimensional replica-exchange method for predicting
374 protein–ligand binding structures. *J. Comput. Chem.* **34**, 2601–2614 (2013).

- 375 27. Laio, A. & Parrinello, M. Escaping free-energy minima. *Proc. Natl. Acad. Sci.* **99**, 12562–12566
376 (2002).
- 377 28. Tiwary, P. & Parrinello, M. From Metadynamics to Dynamics. *Phys. Rev. Lett.* **111**, (2013).
- 378 29. Miao, Y., Feher, V. A. & McCammon, J. A. Gaussian accelerated molecular dynamics:
379 Unconstrained enhanced sampling and free energy calculation. *J. Chem. Theory Comput.* **11**,
380 3584–3595 (2015).
- 381 30. Sinko, W., Miao, Y., de Oliveira, C. A. F. & McCammon, J. A. Population based reweighting of
382 scaled molecular dynamics. *J. Phys. Chem. B* **117**, 12759–12768 (2013).
- 383 31. Schuetz, D. A. *et al.* Predicting Residence Time and Drug Unbinding Pathway through Scaled
384 Molecular Dynamics. *J. Chem. Inf. Model.* **59**, 535–549 (2018).
- 385 32. Huber, G. A. & Kim, S. Weighted-ensemble Brownian dynamics simulations for protein
386 association reactions. *Biophys. J.* **70**, 97–110 (1996).
- 387 33. Zuckerman, D. M. & Chong, L. T. Weighted ensemble simulation: review of methodology,
388 applications, and software. *Annu. Rev. Biophys.* **46**, 43–57 (2017).
- 389 34. Dickson, A. & Brooks III, C. L. WExplore: hierarchical exploration of high-dimensional spaces
390 using the weighted ensemble algorithm. *J. Phys. Chem. B* **118**, 3532–3542 (2014).
- 391 35. Harada, R. & Kitao, A. Parallel cascade selection molecular dynamics (PaCS-MD) to generate
392 conformational transition pathway. *J. Chem. Phys.* **139**, 07B611_1 (2013).
- 393 36. Bowman, G. R., Pande, V. S. & Noé, F. *An introduction to Markov state models and their*
394 *application to long timescale molecular simulation.* vol. 797 (Springer Science & Business Media,
395 2013).

- 396 37. Nawrocki, G., Karaboga, A., Sugita, Y. & Feig, M. Effect of protein--protein interactions and
397 solvent viscosity on the rotational diffusion of proteins in crowded environments. *Phys. Chem.*
398 *Chem. Phys.* **21**, 876–883 (2019).
- 399 38. Patel, A. *et al.* ATP as a biological hydrotrope. *Science (80-.)*. **356**, 753–756 (2017).
- 400 39. Thomas, S. M. & Brugge, J. S. Cellular functions regulated by Src family kinases. *Annu. Rev. Cell*
401 *Dev. Biol.* **13**, 513–609 (1997).
- 402 40. Yang, S., Banavali, N. K. & Roux, B. Mapping the conformational transition in Src activation by
403 cumulating the information from multiple molecular dynamics trajectories. *Proc. Natl. Acad. Sci.*
404 **106**, 3776–3781 (2009).
- 405 41. Meng, Y., Lin, Y. & Roux, B. Computational Study of the “DFG-Flip” Conformational
406 Transition in c-Abl and c-Src Tyrosine Kinases. *J. Phys. Chem. B* **119**, 1443–1456 (2015).
- 407 42. Shukla, D., Meng, Y., Roux, B. & Pande, V. S. Activation pathway of Src kinase reveals
408 intermediate states as targets for drug design. *Nat. Commun.* **5**, 3397 (2014).
- 409 43. Foda, Z. H., Shan, Y., Kim, E. T., Shaw, D. E. & Seeliger, M. A. A dynamically coupled allosteric
410 network underlies binding cooperativity in Src kinase. *Nat. Commun.* **6**, 5939 (2015).
- 411 44. Sultan, M. M., Kiss, G. & Pande, V. S. Towards simple kinetic models of functional dynamics for
412 a kinase subfamily. *Nat. Chem.* **10**, 903–909 (2018).
- 413 45. Tsai, C.-C., Yue, Z. & Shen, J. How Electrostatic Coupling Enables Conformational Plasticity in a
414 Tyrosine Kinase. *J. Am. Chem. Soc.* **141**, 15092–15101 (2019).
- 415 46. Mondal, J., Friesner, R. A. & Berne, B. J. Role of desolvation in thermodynamics and kinetics of
416 ligand binding to a kinase. *J. Chem. Theory Comput.* **10**, 5696–5705 (2014).

- 417 47. Tiwary, P., Mondal, J. & Berne, B. J. How and when does an anticancer drug leave its binding
418 site? *Sci. Adv.* **3**, e1700014 (2017).
- 419 48. Re, S., Oshima, H., Kasahara, K., Kamiya, M. & Sugita, Y. Encounter complexes and hidden
420 poses of kinase-inhibitor binding on the free-energy landscape. *Proc. Natl. Acad. Sci.* **116**, 18404–
421 18409 (2019).
- 422 49. Hanke, J. H. *et al.* Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor
423 Study of Lck-and FynT-dependent T cell activation. *J. Biol. Chem.* **271**, 695–701 (1996).
- 424 50. Sugita, Y., Kitao, A. & Okamoto, Y. Multidimensional replica-exchange method for free-energy
425 calculations. *J. Chem. Phys.* **113**, 6042–6051 (2000).
- 426 51. Shan, Y. *et al.* How does a drug molecule find its target binding site? *J. Am. Chem. Soc.* **133**,
427 9181–9183 (2011).
- 428 52. Cowan-Jacob, S. W. *et al.* The crystal structure of a c-Src complex in an active conformation
429 suggests possible steps in c-Src activation. *Structure* **13**, 861–871 (2005).
- 430 53. Aumiller Jr, W. M., Davis, B. W., Hatzakis, E. & Keating, C. D. Interactions of macromolecular
431 crowding agents and cosolutes with small-molecule substrates: effect on horseradish peroxidase
432 activity with two different substrates. *J. Phys. Chem. B* **118**, 10624–10632 (2014).
- 433 54. Northrup, S. H., Allison, S. A. & McCammon, J. A. Brownian dynamics simulation of diffusion-
434 influenced bimolecular reactions. *J. Chem. Phys.* **80**, 1517–1524 (1984).
- 435 55. Luty, B. A., McCammon, J. A. & Zhou, H.-X. Diffusive reaction rates from Brownian dynamics
436 simulations: Replacing the outer cutoff surface by an analytical treatment. *J. Chem. Phys.* **97**,
437 5682–5686 (1992).
- 438 56. Votapka, L. W. & Amaro, R. E. Multiscale Estimation of Binding Kinetics Using Brownian
439 Dynamics, Molecular Dynamics and Milestoning. *PLOS Comput. Biol.* **11**, e1004381 (2015).

- 440 57. Votapka, L. W., Jagger, B. R., Heyneman, A. L. & Amaro, R. E. SEEKR: Simulation Enabled
441 Estimation of Kinetic Rates, A Computational Tool to Estimate Molecular Kinetics and Its
442 Application to Trypsin--Benzamidine Binding. *J. Phys. Chem. B* **121**, 3597–3606 (2017).
- 443 58. Gomez, D. & Klumpp, S. Biochemical reactions in crowded environments: revisiting the effects of
444 volume exclusion with simulations. *Front. Phys.* **3**, (2015).
- 445 59. Zimmerman, S. B. & Pfeiffer, B. H. Macromolecular crowding allows blunt-end ligation by DNA
446 ligases from rat liver or Escherichia coli. *Proc. Natl. Acad. Sci.* **80**, 5852–5856 (1983).
- 447 60. Zhou, H.-X. Effect of mixed macromolecular crowding agents on protein folding. *Proteins Struct.*
448 *Funct. Bioinforma.* **72**, 1109–1113 (2008).
- 449 61. Dong, H., Qin, S. & Zhou, H.-X. Effects of Macromolecular Crowding on Protein Conformational
450 Changes. *PLoS Comput. Biol.* **6**, e1000833 (2010).
- 451 62. Moebitz, H. The ABC of protein kinase conformations. *Biochim. Biophys. Acta (BBA)-Proteins*
452 *Proteomics* **1854**, 1555–1566 (2015).
- 453 63. Bujacz, A. Structures of bovine, equine and leporine serum albumin. *Acta Crystallogr. Sect. D -*
454 *Biol. Crystallogr.* **68**, 1278–1289 (2012).
- 455 64. Lindorff-Larsen, K. *et al.* Improved side-chain torsion potentials for the Amber ff99SB protein
456 force field. *Proteins Struct. Funct. Bioinforma.* **78**, 1950–1958 (2010).
- 457 65. Hornak, V. *et al.* Comparison of multiple Amber force fields and development of improved
458 protein backbone parameters. *Proteins Struct. Funct. Bioinforma.* **65**, 712–725 (2006).
- 459 66. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of
460 simple potential functions for simulating liquid water. *J. Chem. Phys.* **79**, 926–935 (1983).

- 461 67. Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A. & Case, D. A. Development and testing of
462 a general amber force field. *J. Comput. Chem.* **25**, 1157–1174 (2004).
- 463 68. Jung, J. *et al.* GENESIS: a hybrid-parallel and multi-scale molecular dynamics simulator with
464 enhanced sampling algorithms for biomolecular and cellular simulations. *Wiley Interdiscip. Rev.*
465 *Comput. Mol. Sci.* **5**, 310–323 (2015).
- 466 69. Kobayashi, C. *et al.* GENESIS 1.1: A hybrid-parallel molecular dynamics simulator with
467 enhanced sampling algorithms on multiple computational platforms. *J. Comput. Chem.* **38**, 2193–
468 2206 (2017).
- 469 70. Katsura, K. *et al.* A reproducible and scalable procedure for preparing bacterial extracts for cell-
470 free protein synthesis. *J. Biochem.* **162**, 357–369 (2017).
- 471 71. Katsura, K. *et al.* Phosphorylated and non-phosphorylated HCK kinase domains produced by cell-
472 free protein expression. *Protein Expr. Purif.* **150**, 92–99 (2018).

473

474 **Acknowledgements (optional)**

475 Keep acknowledgements brief and do not include thanks to anonymous referees or editors, or effusive
476 comments. Grant or contribution numbers may be acknowledged. We acknowledge the computing time
477 granted by RIKEN Advanced Center for Computing and Communication (HOKUSAI GreatWave and
478 BigWaterfall), RIKEN Center for Computational Science (K computer), and HPCI system (Project ID:
479 hp170254, hp180201, hp180274, hp190097, hp190181, hp200129, hp200135). This research was
480 supported by MEXT as "Priority Issue on Post-K computer" (Building Innovative Drug Discovery
481 Infrastructure Through Functional Control of Biomolecular Systems) (to Y.S.), "Program for Promoting
482 Researches on the Supercomputer Fugaku" (Biomolecular dynamics in a living cell/MD-driven Precision
483 Medicine) (to Y.S.), MEXT Grant-in-Aid for KIBAN (S) (19H05645) (to Y.S.), RIKEN pioneering projects
484 "Dynamic Structural Biology" and "Glycolipidologue Initiative" (to Y.S.). Funding was provided by the

485 National Science Foundation grant MCB 1817307 (to M.F. and G.N.), by the National Institutes of Health
486 grant R35 GM126948 (to M.F.). Computer time was used on the Anton2 special-purpose supercomputer at
487 the Pittsburgh Supercomputing Center (PSCA18053P). We thank Mr. Kazuharu Hanada and Dr. Kazushige
488 Katsura for their technical assistance on the experiments.

489 **Ethics declarations**

490 Competing interests

491 The authors declare no competing interests.

492 **Supplementary Information**

493 Supporting information is available for this paper.

494

Figures




Figure 1

Spatial distribution functions (SDF) of (a) PP1 and (b) BSA around c-Src kinase. In the case of BSA-SDF, C α atoms are used for analysis. The PP1-SDF is shown as isosurface at 0.5% (transparent) and 1.5% occupancies (solid). For BSA-SDF, the isosurface at 1.0% occupancy is shown.




Figure 2

Reduced efficacy of PP1 inhibitor in the presence of the crowder (BSA) proteins. (a) The probability of finding PP1 in the bulk water region, on c-Src kinase, and on the BSAs as functions of the protein volume fraction. (b) Enzymatic activity of c-Src kinase in the dilute solution ($[c\text{-Src}] = 65.7 \text{ nM}$) and in the crowded solution ($[c\text{-Src}] = 65.7 \text{ nM}$, $[\text{BSA}] = 12.7 \text{ }\mu\text{M}$ (5 mg/ml)). Error bars of (a) and (b) represent the standard error of the mean from seven trajectories and three independent assays, respectively.




Figure 3

Binding trajectories projected onto the two-dimensional free energy landscapes (FELs) obtained from the gREST/REUS simulations in the dilute solution. (a) Definition of azimuth angles (θ , ξ) for describing the relative position (See Supporting information for the detail). (b) The major binding pathway in the dilute solution obtained from the gREST/REUS simulation in different conditions. Left panel: simulation without any restraints (free), Right panel: simulation in which the residues outside the binding pocket is kept close to the crystal structure. E, I, B*, and B respectively indicate encounter complex, intermediate, pre-bound, and bound states. The subscript r denotes the presence of the restraints. (c, d) The binding trajectories in the dilute solution and in the crowded solution (Src8BSA) projected onto the 2D-FEL from 'free' simulation and that from 'restraint' simulation, respectively.




Figure 4

Distribution of the TYR-in and TYR-out states of c-Src kinase. (a) Tyr-in state structure together with a binding trajectory in the dilute solution. (b) Tyr-out state structure with binding trajectory in the dilute and crowded solution (Src8BSA). Red, blue, and green spheres represent the PP1 bound position in the crystal structure, representative binding pathways in dilute and crowded solutions, respectively. Encounter states in the pathways are circled. (c) Distribution for Tyr82-Gly86 distance, $g(d)$. The distance between Tyr82 and Gly86 in a crystal structure of c-Src kinase in complex with an inhibitor (ID: 1Y57) is shown with dashed line for comparison.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [MovieS1.mov](#)
- [MovieS2.mov](#)
- [SINatComm20200904.docx](#)